Sort
82,697 grants matching “vaccine development”
Immunologic &Virologic Features of Early HIV Infection
$1,939,095University Of California San Francisco · U01 · FY2004 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,939,033Jae U Jung · University Of Southern California · U19 · FY2010 · AI
Centers for AIDS Research (CFAR)
$1,938,987Kent J. Weinhold · Duke University · P30 · FY2016 · AI
Development Of A Multicomponent HIV-1 Recombinant Adenoviral Vector Vaccine
$1,938,372Kimberly Wallace · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,936,252Jae U Jung · University Of Southern California · U19 · FY2012 · AI
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
$1,936,000Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2022 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,936,000Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2022 · IP
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,935,998Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2022 · IP
Development of therapeutic pan-Alphavirus human monoclonal antibodies
$1,935,706Michael S. Diamond · La Jolla Institute For Immunology · U19 · FY2022 · AI
Optimizing HIV immunogen-BCR interactions for vaccine development
$1,935,501Leonidas A Stamatatos · Seattle Biomedical Research Institute · P01 · FY2011 · AI
Cancer Immune Monitoring and Analysis Center
$1,934,873Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · U24 · FY2025 · CA
Chiang Mai University HIV/AIDS Clinical Trials Unit
$1,934,836Thira Sirisanthana · Chiang Mai University · U01 · FY2008 · AI
Structural Biology of Influenza Epitopes
$1,934,462Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Structure-guided immunogens to elicit pan-coronavirus B cell responses
$1,934,136Aaron Gregory Schmidt · Washington University · P01 · FY2022 · AI
San Francisco Bay Clinical Trials Unit
$1,934,121Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2020 · AI
Aging and Immunity to Infections
$1,934,107Susan L Swain · Trudeau Institute, Inc. · P01 · FY2007 · AG
Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)
$1,933,277Casey Koontz · Leidos, Inc. · N01 · FY2016 · AI
Center for Experimental Infectious Disease Research
$1,932,834Konstantin G Kousoulas · Louisiana State Univ A&M Col Baton Rouge · P20 · FY2009 · RR
HIV VACCINE CLINICAL TRIALS UNIT
$1,932,451Vanderbilt University · U01 · FY2004 · AI
Host-pathogen competition in IFN mediated antiviral defense
$1,932,378Jae U Jung · University Of Southern California · U19 · FY2011 · AI
ENHANCING T CELL THERAPY OF CANCER
$1,932,287Helen E Heslop · Baylor College Of Medicine · P01 · FY2017 · CA
Enhancing T Cell Therapy of Cancer
$1,932,287Helen E Heslop · Baylor College Of Medicine · P01 · FY2015 · CA
Enhancing T Cell Therapy of Cancer
$1,932,287Helen E Heslop · Baylor College Of Medicine · P01 · FY2013 · CA
Enhancing T Cell Therapy of Cancer
$1,932,287Helen E Heslop · Baylor College Of Medicine · P01 · FY2016 · CA
Cape Town Clinical Trials Unit (CT-CTU) for HIV/AIDS Prevention & Treatment
$1,931,860Robin Wood · University Of Cape Town · UM1 · FY2013 · AI